Extracellular Ca(2+) Modulates ADP-evoked Aggregation Through Altered Agonist Degradation: Implications for Conditions Used to Study P2Y Receptor Activation
Overview
Affiliations
ADP is considered a weak platelet agonist due to the limited aggregation responses it induces in vitro at physiological concentrations of extracellular Ca(2+) [(Ca(2+) )(o) ]. Lowering [Ca(2+) ](o) paradoxically enhances ADP-evoked aggregation, an effect that has been attributed to enhanced thromboxane A(2) production. This study examined the role of ectonucleotidases in the [Ca(2+) ](o) -dependence of platelet activation. Reducing [Ca(2+) ](o) from millimolar to micromolar levels converted ADP (10 μmol/l)-evoked platelet aggregation from a transient to a sustained response in both platelet-rich plasma and washed suspensions. Blocking thromboxane A(2) production with aspirin had no effect on this [Ca(2+) ](o) -dependence. Prevention of ADP degradation abolished the differences between low and physiological [Ca(2+) ](o) resulting in a robust and sustained aggregation in both conditions. Measurements of extracellular ADP revealed reduced degradation in both plasma and apyrase-containing saline at micromolar compared to millimolar [Ca(2+) ](o) . As reported previously, thromboxane A(2) generation was enhanced at low [Ca(2+) ](o) , however this was independent of ectonucleotidase activity(.) P2Y receptor antagonists cangrelor and MRS2179 demonstrated the necessity of P2Y(12) receptors for sustained ADP-evoked aggregation, with a minor role for P2Y(1) . In conclusion, Ca(2+) -dependent ectonucleotidase activity is a major factor determining the extent of platelet aggregation to ADP and must be controlled for in studies of P2Y receptor activation.
The P2Y12 Receptor Antagonist Selatogrel Dissolves Preformed Platelet Thrombi In Vivo.
Crescence L, Kramberg M, Baumann M, Rey M, Roux S, Panicot-Dubois L J Clin Med. 2021; 10(22).
PMID: 34830631 PMC: 8619398. DOI: 10.3390/jcm10225349.
P2X1 Receptors Amplify FcγRIIa-Induced Ca2+ Increases and Functional Responses in Human Platelets.
Ilkan Z, Watson S, Watson S, Mahaut-Smith M Thromb Haemost. 2018; 118(2):369-380.
PMID: 29443373 PMC: 6260114. DOI: 10.1160/TH17-07-0530.
Blood cells: an historical account of the roles of purinergic signalling.
Burnstock G Purinergic Signal. 2015; 11(4):411-34.
PMID: 26260710 PMC: 4648797. DOI: 10.1007/s11302-015-9462-7.
Yang H, Xu S, Li J, Wang L, Wang X Naunyn Schmiedebergs Arch Pharmacol. 2015; 388(9):983-90.
PMID: 25787305 DOI: 10.1007/s00210-015-1113-6.
P2Y(12) receptors in platelets and other hematopoietic and non-hematopoietic cells.
Gachet C Purinergic Signal. 2012; 8(3):609-19.
PMID: 22528678 PMC: 3360102. DOI: 10.1007/s11302-012-9303-x.